The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 2,184,563 | 3,543,122 |
| Payment of operating costs through promissory note | 114,676 | - |
| Interest earned on cash and investments held in trust account | 2,448,266 | 4,005,966 |
| Prepaid expenses | -21,425 | 48,904 |
| Accounts payable and accrued expenses | 155,170 | 70,173 |
| Payment of operating costs through promissory note | - | 83,676 |
| Net cash used in operating activities | -56,108 | -357,899 |
| Investment of cash into trust account | 0 | 231,150,000 |
| Proceeds from issuance of class b ordinary shares to sponsor | - | 0 |
| Net cash used in investing activities | 0 | -231,150,000 |
| Proceeds from promissory note - related party | - | 0 |
| Proceeds from sale of units, net of underwriting discounts paid | 0 | 228,850,000 |
| Proceeds from sale of private placement units | 0 | 3,200,000 |
| Expenses paid by sponsor under share subscription receivable | -56,003 | -354,175 |
| Repayment of promissory note - related party | 0 | 900,000 |
| Payment of offering costs | 0 | -3,195 |
| Net cash provided by financing activities | 56,003 | 231,507,370 |
| Net change in cash | -105 | -529 |
| Cash and cash equivalents at beginning of period | 1,351 | - |
| Cash and cash equivalents at end of period | 717 | - |
Drugs Made In America Acquisition Corp. (DMAA)
Drugs Made In America Acquisition Corp. (DMAA)